Member

Texas Biomedical Research Institute


Texas Biomedical Research Institute is dedicated to pioneering and sharing scientific breakthroughs to protect global communities from infectious diseases. With over 80 years of experience, it combines high-level biocontainment labs, a National Primate Research Center, and a commitment to advancing diagnostics, vaccines, and therapies. The institute also emphasizes education and outreach, providing resources and programs to engage students and teachers in scientific research.

Industries

biotechnology
education
health-care
medical

Nr. of Employees

large (251-1000)

Texas Biomedical Research Institute

P.O. Box 760549, San Antonio, TX 78245-0549


Patents

Cell culture media and methods for generating human alveolar macrophage-like cells

2024-12-24 • US-12173326-B2

View Details

Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins

2020-08-25 • US-10751406-B2

View Details

Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins

2017-08-15 • US-9730996-B2

View Details

Products

CoDe: codon deoptimization tool

Computational tool to recode RNA/DNA sequences via codon-pair deoptimization to attenuate viruses by increasing underrepresented codon pairs without altering amino acid sequences.

Meta-Transcriptome Detector (MTD) pipeline

Bash-executed pipeline for joint analysis of host transcriptome and microbiome using bulk and single-cell RNA-seq; generates count matrices, graphs and summary outputs.

Cell culture media and methods for generating alveolar macrophage–like cells

In vitro differentiation protocol using a surfactant and cytokine mixture to convert blood-derived monocytes into alveolar macrophage–like cells that retain phenotype and function for extended culture.

Involucrin-driven retroviral expression cassette vaccine platform

Vaccine platform using differentiation-specific transcriptional regulatory elements to direct antigen expression in epithelial stem cell lineages for mucosal antigen presentation.

Monoclonal antibodies and antigen-binding fragments for SARS-CoV-2

Human monoclonal antibodies and fragments with broad neutralizing activity described for therapeutic use against SARS-CoV-2 infections.

Compositions and methods for treating Schistosoma infections

Patent-disclosed composition(s) and methods intended to treat Schistosoma infections.

Expertise Areas

  • Infectious disease preclinical research
  • Nonhuman primate model development and management
  • Vaccine and therapeutic discovery and preclinical development
  • Monoclonal antibody discovery and characterization
  • Show More (4)

Key Technologies

  • Biosafety level 4 (BSL-4) operations
  • Biosafety level 3 (BSL-3) operations
  • Nonhuman primate (NHP) models
  • Telemetry for animal studies
  • Show More (9)

Key People

President and Chief Executive Officer

LinkedIn

Bruce Edwards

Executive Vice President, Finance & Administration and Chief Financial Officer

Dr. Cory Hallam

Executive Vice President, Applied Science and Innovation

Director, Southwest National Primate Research Center

View All People

News & Updates

Funding awarded to enhance research capabilities in HIV and TB.

A significant partnership aimed at improving epidemic preparedness.

Deployment of a tested vaccine to combat Marburg virus in Rwanda.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.